Summary

The drugs for vulvovaginal candidiasis market was valued at $1.0 billion in 2023, and is projected to reach $1.6 billion by 2033, growing at a CAGR of 4.4% from 2024 to 2033.
Drugs for vulvovaginal candidiasis are pharmaceutical agents used to treat fungal infections caused by the overgrowth of Candida species in the vaginal and vulvar regions. These drugs aim to alleviate symptoms such as itching, discharge, and inflammation while eradicating the underlying fungal pathogen. Treatment options include topical antifungals (creams and suppositories) and systemic medications (oral antifungals), with varying durations depending on the severity of the infection.

The global drugs for vulvovaginal candidiasis market is witnessing robust growth due to alarming rise in the prevalence of vulvovaginal candidiasis due to factors such as higher rates of diabetes, hormonal fluctuations, and antibiotic use. Studies reveal that vulvovaginal candidiasis is the second most common infection prevalent among women worldwide. According to a study conducted by the National Institutes of Health—one of the world's foremost medical research centers—75% of women experience at least one episode of vulvovaginal candidiasis during their lifetime. This highlights the increasing need for therapeutic drugs for effective treatment. Furthermore, increase in awareness campaigns and educational efforts regarding vaginal health have led to earlier diagnosis and treatment-seeking behavior, thereby propelling the market for r vulvovaginal candidiasis drugs. Moreover, rise in access to over-the-counter antifungals has made treatment accessible to a larger population, particularly in developed regions, which notably contributes toward the market growth. Factors such as sedentary lifestyles, poor hygiene, and the growing use of hormonal contraceptives have further contributed to a higher incidence of vulvovaginal candidiasis, supporting the demand for therapeutic drugs. In addition, availability of treatments through online pharmacies and telemedicine platforms has made it easier for patients to access medications, which is expected to foster the market growth. However, emergence of drug-resistant Candida strains, particularly Candida glabrata and Candida krusei, has reduced the efficacy of commonly used antifungal agents, such as azoles, limiting treatment options. In addition, adverse effects like gastrointestinal discomfort, liver toxicity, and allergic reactions discourage the use of certain systemic antifungal drugs, thus hampering the market growth. On the contrary, the introduction of single-dose oral treatments like fluconazole and innovative formulations such as extended-release suppositories or vaginal tablets has enhanced patient compliance. Such developments are expected to offer remunerative opportunities for the expansion of the global market during the forecast period.

The global drugs for vulvovaginal candidiasis market is segmented into drug class, route of administration, distribution channel, and region. On the basis of the drug class, the market is categorized into clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others. By route of administration, it is classified into oral, intravenous, and topical. Depending on distribution channel, it is divided into hospital pharmacy, retail pharmacy, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings
By drug class, the fluconazole segment is expected to dominate the market from 2024 to 2033.
On the basis of route of administration, the oral segment is anticipated to exhibit the highest growth during the forecast period.
Depending on distribution channel, the retail pharmacy segment is projected to grow at a notable pace in the coming years.
Region wise, North America emerged as the most lucrative market for vulvovaginal candidiasis drugs; however, Asia-Pacific is likely to register the highest growth throughout the forecast period.

Competition Analysis
Competitive analysis and profiles of the major players in the global drugs for vulvovaginal candidiasis market include Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Bayer AG, Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc., Zydus Lifesciences Ltd., Bristol-Myers Squibb Company, and Amneal Pharmaceuticals LLC. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● New Product Development/ Product Matrix of Key Players
● Regulatory Guidelines
● Additional company profiles with specific to client's interest
● Additional country or region analysis- market size and forecast
● Expanded list for Company Profiles
● Historic market data
● Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Drug Class
● Clotrimazole
● Nystatin
● Fluconazole
● Ketoconazole
● Terbinafine
● Terconazole
● Others
By Route Of Administration
● Oral
● Intravenous
● Topical
By Distribution Channel
● Hospital Pharmacy
● Retail Pharmacy
● Online Providers
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Astellas Pharma Inc
○ Mycovia Pharmaceuticals, Inc.
○ Bayer AG
○ Basilea Pharmaceutica Ltd
○ Scynexis, Inc.
○ Grupo Ferrer Internacional S.A.
○ Pfizer, Inc.
○ Zydus Lifesciences Ltd.
○ Bristol-Myers Squibb Company
○ Amneal Pharmaceuticals LLC

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug Class
4.2. Clotrimazole
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Nystatin
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Fluconazole
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Ketoconazole
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Terbinafine
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
4.7. Terconazole
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, By Region
4.7.3. Market Share Analysis, By Country
4.8. Others
4.8.1. Key Market Trends, Growth Factors and Opportunities
4.8.2. Market Size and Forecast, By Region
4.8.3. Market Share Analysis, By Country
CHAPTER 5: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Route Of Administration
5.2. Oral
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Intravenous
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Topical
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacy
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Retail Pharmacy
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Providers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Drug Class
7.2.3. Market Size and Forecast, By Route Of Administration
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Drugs for Vulvovaginal Candidiasis Market
7.2.6.1. Market Size and Forecast, By Drug Class
7.2.6.2. Market Size and Forecast, By Route Of Administration
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Drugs for Vulvovaginal Candidiasis Market
7.2.7.1. Market Size and Forecast, By Drug Class
7.2.7.2. Market Size and Forecast, By Route Of Administration
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Drugs for Vulvovaginal Candidiasis Market
7.2.8.1. Market Size and Forecast, By Drug Class
7.2.8.2. Market Size and Forecast, By Route Of Administration
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Drug Class
7.3.3. Market Size and Forecast, By Route Of Administration
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Drugs for Vulvovaginal Candidiasis Market
7.3.6.1. Market Size and Forecast, By Drug Class
7.3.6.2. Market Size and Forecast, By Route Of Administration
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. France Drugs for Vulvovaginal Candidiasis Market
7.3.7.1. Market Size and Forecast, By Drug Class
7.3.7.2. Market Size and Forecast, By Route Of Administration
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. UK Drugs for Vulvovaginal Candidiasis Market
7.3.8.1. Market Size and Forecast, By Drug Class
7.3.8.2. Market Size and Forecast, By Route Of Administration
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Italy Drugs for Vulvovaginal Candidiasis Market
7.3.9.1. Market Size and Forecast, By Drug Class
7.3.9.2. Market Size and Forecast, By Route Of Administration
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. Spain Drugs for Vulvovaginal Candidiasis Market
7.3.10.1. Market Size and Forecast, By Drug Class
7.3.10.2. Market Size and Forecast, By Route Of Administration
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Drugs for Vulvovaginal Candidiasis Market
7.3.11.1. Market Size and Forecast, By Drug Class
7.3.11.2. Market Size and Forecast, By Route Of Administration
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Drug Class
7.4.3. Market Size and Forecast, By Route Of Administration
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Drugs for Vulvovaginal Candidiasis Market
7.4.6.1. Market Size and Forecast, By Drug Class
7.4.6.2. Market Size and Forecast, By Route Of Administration
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. China Drugs for Vulvovaginal Candidiasis Market
7.4.7.1. Market Size and Forecast, By Drug Class
7.4.7.2. Market Size and Forecast, By Route Of Administration
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. India Drugs for Vulvovaginal Candidiasis Market
7.4.8.1. Market Size and Forecast, By Drug Class
7.4.8.2. Market Size and Forecast, By Route Of Administration
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. Australia Drugs for Vulvovaginal Candidiasis Market
7.4.9.1. Market Size and Forecast, By Drug Class
7.4.9.2. Market Size and Forecast, By Route Of Administration
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. South Korea Drugs for Vulvovaginal Candidiasis Market
7.4.10.1. Market Size and Forecast, By Drug Class
7.4.10.2. Market Size and Forecast, By Route Of Administration
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Market
7.4.11.1. Market Size and Forecast, By Drug Class
7.4.11.2. Market Size and Forecast, By Route Of Administration
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Drug Class
7.5.3. Market Size and Forecast, By Route Of Administration
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Drugs for Vulvovaginal Candidiasis Market
7.5.6.1. Market Size and Forecast, By Drug Class
7.5.6.2. Market Size and Forecast, By Route Of Administration
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. Saudi Arabia Drugs for Vulvovaginal Candidiasis Market
7.5.7.1. Market Size and Forecast, By Drug Class
7.5.7.2. Market Size and Forecast, By Route Of Administration
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. South Africa Drugs for Vulvovaginal Candidiasis Market
7.5.8.1. Market Size and Forecast, By Drug Class
7.5.8.2. Market Size and Forecast, By Route Of Administration
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Drugs for Vulvovaginal Candidiasis Market
7.5.9.1. Market Size and Forecast, By Drug Class
7.5.9.2. Market Size and Forecast, By Route Of Administration
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Astellas Pharma Inc
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Mycovia Pharmaceuticals, Inc.
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Bayer AG
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Basilea Pharmaceutica Ltd
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Scynexis, Inc.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Grupo Ferrer Internacional S.A.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Pfizer, Inc.
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Zydus Lifesciences Ltd.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Bristol-Myers Squibb Company
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Amneal Pharmaceuticals LLC
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments